Anemia News and Research

RSS

Anemia is a decrease in normal number of red blood cells (RBCs) or less than the normal quantity of hemoglobin in the blood. However, it can include decreased oxygen-binding ability of each hemoglobin molecule due to deformity or lack in numerical development as in some other types of hemoglobin deficiency. The three main classes of anemia include excessive blood loss (acutely such as a hemorrhage or chronically through low-volume loss), excessive blood cell destruction (hemolysis) or deficient red blood cell production (ineffective hematopoiesis). Anemia is the most common disorder of the blood. There are several kinds of anemia, produced by a variety of underlying causes. Anemia can be classified in a variety of ways, based on the morphology of RBCs, underlying etiologic mechanisms, and discernible clinical spectra, to mention a few.

FDA grants accelerated approval for Darzalex to treat patients with multiple myeloma

Today the U.S. Food and Drug Administration granted accelerated approval for Darzalex (daratumumab) to treat patients with multiple myeloma who have received at least three prior treatments. Darzalex is the first monoclonal antibody approved for treating multiple myeloma.

17 Nov 2015

Drug combination produces long-term responses in patients with mantle cell lymphoma

New research from Moffitt Cancer Center and its collaborators find that the drug combination rituximab plus lenalidomide was effective and produced long-term responses in patients with mantle cell lymphoma.

13 Nov 2015

Boston Children's Hospital selects Vijay G. Sankaran to receive Rising Star Award

Saluting his spectacular track record to date of innovative research on red blood cell disorders and his future promise as a physician/scientist, Boston Children's Hospital has selected Vijay G. Sankaran, MD, PhD, of Dana-Farber/Boston Children's Cancer and Blood Disorders Center to receive the Rising Star Award at the hospital's third annual Global Pediatric Innovation Summit, Taking on Tomorrow (#PedInno15).

11 Nov 2015

Phase I clinical trial shows investigational anticancer therapeutic is safe, tolerable in lymphoma patients

Results from a phase I clinical trial showed that the first-in-class, investigational, anticancer therapeutic pevonedistat was safe, tolerable, and had some anticancer activity in heavily pretreated patients with relapsed/refractory lymphoma.

11 Nov 2015

New clinical chemistry analyzer launched by EKF at Medica 2015

EKF, launched the Altair™ 240 clinical chemistry analyzer to the European market at Medica 2015, Düsseldorf, 16-19th November.

From EKF Diagnostics 10 Nov 2015

AACR rapid and dramatic responses in TRK fusion patients

Loxo Oncology, Inc., a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, today announced new results from its Phase 1 open-label, dose-escalation trial of LOXO-101, a selective inhibitor of tropomyosin receptor kinase (TRK) signaling molecules, and the first preclinical data for its RET and FGFR programs. The data are being presented at the 2015 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston.

9 Nov 2015

Agios announces data from dose-escalation phase 1 study of AG-120 in patients with IDH1 mutant positive advanced solid tumors

Agios Pharmaceuticals, Inc., a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced the first data from the dose-escalation portion of the ongoing Phase 1 study evaluating single agent AG-120, a first-in-class, oral, selective, potent inhibitor of mutant isocitrate dehydrogenase-1 (IDH1), in advanced solid tumors. The data are being presented today at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston. AG-120 is being developed in collaboration with Celgene.

9 Nov 2015

Stem-cell scientists discover new view of how human blood is made

Stem-cell scientists led by Dr. John Dick have discovered a completely new view of how human blood is made, upending conventional dogma from the 1960s.

6 Nov 2015

UCSD researchers suggest that cancer-related mutations common in patients with low blood counts

Patients with unexplained low blood counts and abnormally mutated cells who do not fit the diagnostic criteria for recognized blood cancers should be described as having clonal cytopenias of undetermined significance (CCUS), suggest University of California, San Diego School of Medicine researchers in a recent paper published in the journal Blood.

4 Nov 2015

Researchers find strong associations between hunger and poor health

It may come as a surprise that, even after the Great Recession ended in 2009, almost 50 million people in the United States are food insecure -- that is, they lack access to adequate food because of limited money or other resources. University of Illinois economist Craig Gundersen and University of Kentucky's James Ziliak examined recent research on food insecurity and its association with poor health and offer suggestions, including that doctors screen for hunger.

3 Nov 2015

Lab experiment leads researchers to major red blood cell discovery

A bizarre result of a routine lab experiment has led researchers at the University of Virginia School of Medicine to an unexpected new way to trigger the production of red blood cells. This could represent a significant step forward in the battle against anemia, benefitting people with diabetes, people with kidney disease or cancer, and older people for whom anemia can become a chronic problem.

3 Nov 2015

Deaths from avoidable risk factors: an interview with Dr Ali Mokdad, IHME

The study showed that about thirty percent to maybe half of the leading causes of death in the world are preventable. These are risk factors that you could manage and thus you could prevent a lot of premature deaths.

3 Nov 2015

$Viking begins VK5211 Phase 2 trial in patients recovering from hip fracture$

Viking begins VK5211 Phase 2 trial in patients recovering from hip fracture

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders, today announced the initiation of dosing in the company's Phase 2 clinical trial of VK5211 in patients who recently suffered a hip fracture.

3 Nov 2015

Key protein controls stem cell properties that could make them useful in regenerative medicine

A key protein controls stem cell properties that could make them more useful in regenerative medicine, according to a study led by Mount Sinai researchers and published online today in the journal Cell Stem Cell.

31 Oct 2015

Patients with treatment-resistant autoimmune blood conditions may benefit from sirolimus

The immunosuppressant sirolimus is an effective and safe steroid-sparing therapy for children and young adults with highly treatment-resistant autoimmune blood conditions, according to a study published online today in Blood, the Journal of the American Society of Hematology.

27 Oct 2015

FDA approves Yondelis (trabectedin) for treatment of specific soft tissue sarcomas

The U.S. Food and Drug Administration today approved Yondelis (trabectedin), a chemotherapy, for the treatment of specific soft tissue sarcomas (STS) – liposarcoma and leiomyosarcoma – that cannot be removed by surgery (unresectable) or is advanced (metastatic).

24 Oct 2015

Viking successfully completes safety, tolerability and pharmacokinetic study of VK5211 in elderly subjects

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders, today announced the successful completion of a short-term safety, tolerability, and pharmacokinetic study of VK5211 in healthy elderly subjects. VK5211, the company's lead program for muscle and bone disorders, is an orally available, non-steroidal selective androgen receptor modulator (SARM) being developed for the treatment of patients recovering from non-elective hip fracture surgery.

20 Oct 2015

Anemia News and Research

Further Reading

FDA grants accelerated approval for Darzalex to treat patients with multiple myeloma

Drug combination produces long-term responses in patients with mantle cell lymphoma

Boston Children's Hospital selects Vijay G. Sankaran to receive Rising Star Award

Phase I clinical trial shows investigational anticancer therapeutic is safe, tolerable in lymphoma patients

New clinical chemistry analyzer launched by EKF at Medica 2015

AACR rapid and dramatic responses in TRK fusion patients

Agios announces data from dose-escalation phase 1 study of AG-120 in patients with IDH1 mutant positive advanced solid tumors

Stem-cell scientists discover new view of how human blood is made

UCSD researchers suggest that cancer-related mutations common in patients with low blood counts

Researchers find strong associations between hunger and poor health

Lab experiment leads researchers to major red blood cell discovery

Deaths from avoidable risk factors: an interview with Dr Ali Mokdad, IHME

Viking begins VK5211 Phase 2 trial in patients recovering from hip fracture

Key protein controls stem cell properties that could make them useful in regenerative medicine

Patients with treatment-resistant autoimmune blood conditions may benefit from sirolimus

FDA approves Yondelis (trabectedin) for treatment of specific soft tissue sarcomas

Viking successfully completes safety, tolerability and pharmacokinetic study of VK5211 in elderly subjects

CNIO researchers identify molecular mechanisms that determine cancer predisposition in DBA patients

Study shows why cancer anemia therapy stimulates tumor growth

Study explains why anemia is a common side effect of anti-cancer drugs

Industry Focus eBook - Forensics & toxicology (2nd edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News